The trial evaluates Orelabrutinib in combination with Bendamustine and Rituximab for transplant-ineligible patients with intermediate- to high-risk mantle cell lymphoma (MCL). Given the high unmet need in this patient population, successful outcomes could position Orelabrutinib as a key therapeutic option, potentially capturing significant market share in the oncology space. The competitive landscape includes other BTK inhibitors and combination therapies, necessitating a robust efficacy profile to differentiate Orelabrutinib. Diligence should focus on regulatory pathways and market access strategies, particularly in regions with high incidence rates of MCL.